Pieris slammed with FDA hold; Biogen adds PhIV for Spinraza
→ Boston-based Pieris $PIRS has been forced to hit the brakes on a slate of Phase I studies for its 4-1BB/HER2 fusion protein drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
